Avant Diagnostics Inc fka ADVX

[General_Sevier]

Nice of the two officers (and only employees) giving themselves 62% of the company and diluting existing shareholders interest. They just gave themselves 68 million shares. They didn't even sent out an "open thank you letter" to legacy shareholders.

http://www.sec.gov/Archives/edgar/data/1451929/000101968714004845/amerliberty_8k-122914.htm

Now the legacy shareholders will get about 1.17% of the final number of shares that will be O/S (74 million shares) after the 17:1 reverse split and the reverse merger.

The fledgling Avant that is approximately 5 years behind their own timelines laid out in 2009 will now be the business of OREO but will have a valuation of $20 to $25 million.

It might be worth $3 to $5 million ------ IMHO.

ARYC owns over 50% of Avant and despite it's life science tools business as well, ARYC's market cap, even when adding in all their preferred stock, is around $8 million. ARYC's normalized revenue is probably about $2.8 million a year (and at below or around breakeven). IMHO, ignore the goofy $1.5 million they have claimed as revenue (an BTW, ARYC immediately reserved the entire amount).

Happy trading but any "investors" need to do basic DD.

This post isn't advocating ARYC as a good deal either. IMHO, it highlights how far OREO needs to fall just to normalize with ARYC. And I think ARYC is probably overvalued at 10 cents.